Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

BCRX BioCryst Pharmaceuticals Inc
$6.78 -0.29% -0.02
Notify me if price changes either direction
Interactive Brokers Logotype

Buy BCRX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 1.7B
Enterprise value 1.9B
Trailing PE -15.767442348392
Forward PE 17.041874
PEG Ratio 0.084901612645185
Enterprise to EBITDA 23.542
Enterprise to revenue 3.157
Price to book MRQ -3.6737141916803
Price to sales TTM 2.7954307

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 599.8M
EBITDA 13.4M
Diluted EPS TTM -0.05
Total Cash (MRQ) 212.9M
Current ratio (MRQ) 1.87
Operating Cash Flow (TTM) 50.2M

BCRX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent BCRX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.